Skip to content

Clinical trials

Diabetes Mellitus, Type 1 trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Country / region: United Kingdom Clear all

256 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20013
20023
20032
20046
20057
20067
20076
20085
20097
20106
201111
201216
201315
201413
201513
201614
201711
201811
201917
202013
202119
20229
202314
20246
202512
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed176
Recruiting22
Unknown status20
Terminated18
Active, not recruiting8
Withdrawn5
Not yet recruiting4
Suspended2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S33
University of Cambridge25
Imperial College London20
Medtronic MiniMed, Inc.9
King's College London8
Manchester University NHS Foundation Trust8
Sanofi6
University of Oxford6
Royal Devon and Exeter NHS Foundation Trust5
Eli Lilly and Company4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 1256
Diabetes Mellitus75
Diabetes Mellitus, Type 238
Hypoglycemia19
Autoimmune Diseases9
Endocrine System Diseases8
Glucose Metabolism Disorders8
Insulin Resistance5
Hyperglycemia4
Anxiety Disorders3

Trials

Showing 1 to 25 of 256. Each trial links to its page on Pharma Observatory.

156 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.